PT-141 (Bremelanotide) Therapy

PT-141, also known as Bremelanotide, is a synthetic peptide therapy designed to treat hypoactive sexual desire disorder (HSDD) in premenopausal women. As a melanocortin receptor agonist, it targets the central nervous system pathways associated with sexual arousal, offering an alternative to traditional PDE5 inhibitors. This FDA-approved treatment is administered as an on-demand subcutaneous injection, providing increased sexual desire and reduced distress related to low desire.